Table 1.

Baseline characteristics of older women with breast cancer by types of chemotherapy agents

	Number of patients	Anthracycline (%)	CMF (%)	Taxane (%)	Othera (%)
Overall	6,932	50.7	44.1	15.4	12.4
Year of Dx
1994	377	32.4	62.9	0.5	24.9
1995	376	35.9	61.2	1.1	15.2
1996	392	38.8	61.0	3.6	13.5
1997	503	44.3	55.6	4.2	15.9
1998	613	38.5	52.5	8.7	17.3
1999	645	52.9	41.7	17.7	12.6
2000	1,386	56.5	36.7	25.7	11.7
2001	1,373	56.2	38.8	17.3	8.6
2002	1,267	59.0	34.6	20.9	8.5
Age at Dx, years
68–74	4,543	56.0	40.4	16.1	11.8
75–84	2,303	41.0	51.2	13.7	13.1
85+	86	23.3	48.8	24.4	24.4
Race
White	6,076	50.6	43.9	15.5	12.3
Black	487	52.2	43.7	15.0	12.3
Other	362	49.5	47.0	13.8	13.8
AJCC stage
I	1,185	34.4	54.2	6.5	16.8
II	4,583	51.1	45.5	14.4	10.4
III	1,164	65.5	28.3	28.3	15.8
ER status
Positive	3,767	51.7	42.3	15.1	12.6
Negative	2,106	48.2	48.0	15.2	11.8
Unknown	1,059	51.9	42.9	17.0	12.7
Comorbidity
0	5,144	52.7	42.6	15.9	12.3
1	1,273	46.6	47.1	13.8	13.0
>1	515	40.0	51.5	14.8	12.2
Grade
Well	599	43.2	48.4	13.9	12.4
Moderately	2,318	51.3	43.7	14.9	11.4
Poorly	3,107	53.1	42.7	16.3	12.3
Undifferentiated	176	49.4	44.3	14.8	15.3
Unknown	732	44.7	47.7	14.5	15.4
Surgery type
None	174	60.3	25.3	28.7	21.3
BCS	2,503	46.9	46.9	11.8	13.1
Mastectomy	4,255	52.5	43.2	16.9	11.6

^aOut of 858 patients receiving “Other” chemotherapy, the medications were not classified for 111 (12.9%) of them (only having J9999). A total of 396 of them (46.2%) received Cyclophosphamide without Methotrexate sodium and Flurouracil, 56 received either Methotrexate or Flurouracil, 76 received Trastuzumab, 75 received Carboplatin, 37 received Vincristine, 24 received Vinorelbine, 23 received Etoposide, 14 received Fludarabine, 12 received Floxuridine, 11 received Vinblastine, and 46 received other medications